Kent C. Shih

4.5k total citations · 1 hit paper
54 papers, 2.6k citations indexed

About

Kent C. Shih is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kent C. Shih has authored 54 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 19 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kent C. Shih's work include Polyomavirus and related diseases (11 papers), Glioma Diagnosis and Treatment (10 papers) and Cancer Treatment and Pharmacology (9 papers). Kent C. Shih is often cited by papers focused on Polyomavirus and related diseases (11 papers), Glioma Diagnosis and Treatment (10 papers) and Cancer Treatment and Pharmacology (9 papers). Kent C. Shih collaborates with scholars based in United States, France and Germany. Kent C. Shih's co-authors include Isaac Brownell, Sandra P. D’Angelo, Shailender Bhatia, Michèle Milella, Omid Hamid, Paul Nghiem, Célèste Lebbé, Karl D. Lewis, Patrick Terheyden and Jeffery S. Russell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Kent C. Shih

52 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 933 citations Howard L. Kaufman, Jeffery S. Russell et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Kent C. Shih

Since Specialization

Citations

This map shows the geographic impact of Kent C. Shih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kent C. Shih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kent C. Shih more than expected).

Fields of papers citing papers by Kent C. Shih

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kent C. Shih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kent C. Shih. The network helps show where Kent C. Shih may publish in the future.

Co-authorship network of co-authors of Kent C. Shih

This figure shows the co-authorship network connecting the top 25 collaborators of Kent C. Shih. A scholar is included among the top collaborators of Kent C. Shih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kent C. Shih. Kent C. Shih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma 2024 ·Neuro-Oncology Advances ·Gerald S. Falchook, James Battiste, (unknown), Mythili Shastry, (unknown), (unknown), Ming‐Chieh Shih, Kent C. Shih	0
2	CTNI-64. EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL 2023 ·Neuro-Oncology ·David A. Reardon, Liam Welsh, Kent C. Shih, Toshio Shimizu, Jean‐Charles Goeminne, Birgit Geoerger, Capucine Baldini, Christophe Massard, Yohann Loriot, Shubham Pant, Sameer Farouk Sait, Shibu Thomas, Constance Hammond, (unknown), Spyros Triantos, (unknown), Hussein Sweiti, Olaf Witt	0
3	Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up. 2021 ·Journal of Clinical Oncology ·Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Huiling Xiong, (unknown), Sandra P. D’Angelo	2
4	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma 2019 ·Cancer Immunology Immunotherapy ·Sandra P. D’Angelo, Matthias Hünger, Andrew S. Brohl, Paul Nghiem, Shailender Bhatia, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Michael Schlichting, (unknown), Murtuza Bharmal	17
5	Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II) 2019 ·Journal of Neuro-Oncology ·John D. Hainsworth, Kevin Becker, Tarek Mekhail, Sajeel Chowdhary, Janice F. Eakle, David Wright, Robert M. Langdon, Kathleen J. Yost, (unknown), (unknown), (unknown), (unknown), Mythili Shastry, Howard A. Burris, Kent C. Shih	41
6	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss 2018 ·Clinical Cancer Research ·Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, Christophe Massard, Sergio Bracarda, Albert Font, Jóse Ángel Arranz Arija, Kent C. Shih, George Daniel Rădăvoi, Na Xu, Wai Yee Chan, Han Ma, Steven Gendreau, Ruth Riisnaes, Premal H. Patel, Daniel Maslyar, Viorel Jinga	227
7	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies 2018 ·Clinical Cancer Research ·Drew Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita K. Gandhi, Patrick R. Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, Kent C. Shih	74
8	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma 2018 ·Journal of Neuro-Oncology ·Rimas V. Lukas, Jordi Rodón, Kevin Becker, Eric T. Wong, Kent C. Shih, Mehdi Touat, Marcella Fassò, Stuart Osborne, Luciana Molinero, Carol O’Hear, William Grossman, Joachim M. Baehring	112
9	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial 2018 ·Journal for ImmunoTherapy of Cancer ·Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem	235
10	Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC) 2018 ·Lung Cancer ·John D. Hainsworth, David Waterhouse, Kent C. Shih, Ralph V. Boccia, Victor Priego, Michael McCleod, Fred J. Kudrik, R. Brian Mitchell, Howard A. Burris, F. Anthony Greco, David R. Spigel	6
11	Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures 2018 ·Cancer ·David R. Spigel, Howard A. Burris, F. Anthony Greco, Kent C. Shih, Victor G. Gian, (unknown), Davey B. Daniel, David Waterhouse, (unknown), John V. Heymach, John D. Hainsworth	11
12	Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI) 2017 ·Lung Cancer ·David R. Spigel, Mark S. Rubin, Victor G. Gian, Dianna Shipley, Howard A. Burris, (unknown), Kent C. Shih, Raven Quinn, F. Anthony Greco, John D. Hainsworth	9
13	Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update 2017 ·Cancer Research ·Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Lisa Mahnke, Paul Nghiem	19
14	PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) 2016 ·Annals of Oncology ·Johann S. de Bono, Ugo De Giorgi, Christophe Massard, Sergio Bracarda, Daniel Nava Rodrigues, Ivo Kocák, Albert Font, (unknown), Kent C. Shih, George Daniel Rădăvoi, (unknown), Wen‐Ching Chan, Steven Gendreau, (unknown), Ruth Riisnaes, Matthew Wongchenko, Daniel Maslyar, Viorel Jinga	40
15	A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma 2016 ·Journal of Neuro-Oncology ·Kent C. Shih, Sajeel Chowdhary, (unknown), Alva B. Weir, (unknown), Jeffrey T. Williams, Mythili Shastry, Howard A. Burris, John D. Hainsworth	88
16	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial breakdown → 2016 ·The Lancet Oncology ·Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Gerald P. Linette, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Kevin M. Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem	933
17	A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers 2016 ·Cancer Investigation ·Johanna C. Bendell, Ahmed Zakari, (unknown), David Waterhouse, (unknown), (unknown), Michael McCleod, N. W. Peacock, (unknown), Cassie M. Lane, (unknown), Kent C. Shih	16
18	Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies 2014 ·Drugs ·Kent C. Shih, Hendrik‐Tobias Arkenau, Jeffrey R. Infante	88
19	Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma 2013 ·Melanoma Research ·Ralph J. Hauke, Jeffrey R. Infante, Mark S. Rubin, Kent C. Shih, Edward Arrowsmith, John D. Hainsworth	15
20	Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). 2012 ·Journal of Clinical Oncology ·Victor G. Gian, Mark S. Rubin, Dianna Shipley, Howard A. Burris, Joseph Kaplan, (unknown), Kent C. Shih, Frederick P. Smith, Raven Quinn, Frank A. Greco, John D. Hainsworth, David R. Spigel	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact